Literature DB >> 19127577

How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?

Stanley Fahn1.   

Abstract

The motor complications associated with levodopa therapy, namely, fluctuations in motor response and dyskinesias, occur in the majority of Parkinson's disease patients. These complications can impair a patient's quality of life and even cause pronounced disability. "Off" states that result in freezing of gait and falling are disabling for many patients. Dyskinesias most commonly occur at peak dose and typically alternate with the wearing-off state. Once these problems appear, they usually persist, and the physician needs to make continual adjustments in medications to minimize these problems. Medical treatments should be attempted before treatments such as deep brain stimulation are considered because of the potential adverse effects that are associated with surgery. The timing of surgery, however, is also important because younger patients and less advanced patients tend to have a better outcome. There is thus a need for experienced and knowledgeable physicians and surgeons who are able to handle these motor complications. This review discusses available medications and surgical approaches, and their outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19127577     DOI: 10.1002/ana.21453

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  28 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

Review 2.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

3.  Focus on α4β2* and α6β2* nAChRs for Parkinson's Disease Therapeutics.

Authors:  Xiomara A Pérez; Maryka Quik
Journal:  Mol Cell Pharmacol       Date:  2011

Review 4.  Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders.

Authors:  Maryka Quik; Xiomara A Perez; Sharon R Grady
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

5.  Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization.

Authors:  Tanuja Bordia; Carla Campos; J Michael McIntosh; Maryka Quik
Journal:  J Pharmacol Exp Ther       Date:  2010-03-03       Impact factor: 4.030

Review 6.  G protein-coupled receptor kinases: more than just kinases and not only for GPCRs.

Authors:  Eugenia V Gurevich; John J G Tesmer; Arcady Mushegian; Vsevolod V Gurevich
Journal:  Pharmacol Ther       Date:  2011-08-26       Impact factor: 12.310

Review 7.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 8.  Molecular imaging of levodopa-induced dyskinesias.

Authors:  Flavia Niccolini; Lorenzo Rocchi; Marios Politis
Journal:  Cell Mol Life Sci       Date:  2015-02-15       Impact factor: 9.261

9.  PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking.

Authors:  Gregory Porras; Amandine Berthet; Benjamin Dehay; Qin Li; Laurent Ladepeche; Elisabeth Normand; Sandra Dovero; Audrey Martinez; Evelyne Doudnikoff; Marie-Laure Martin-Négrier; Qin Chuan; Bertrand Bloch; Daniel Choquet; Eric Boué-Grabot; Laurent Groc; Erwan Bezard
Journal:  J Clin Invest       Date:  2012-10-08       Impact factor: 14.808

10.  Parallel dopamine D1 receptor activity dependence of l-Dopa-induced normal movement and dyskinesia in mice.

Authors:  L Li; F-M Zhou
Journal:  Neuroscience       Date:  2013-01-26       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.